Cytokinetics (NASDAQ: CYTK) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Cytokinetics to related companies based on the strength of its institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.
Risk and Volatility
Cytokinetics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Cytokinetics’ rivals have a beta of 5.95, meaning that their average share price is 495% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Cytokinetics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytokinetics currently has a consensus target price of $17.90, suggesting a potential upside of 119.63%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.22%. Given Cytokinetics’ stronger consensus rating and higher probable upside, research analysts clearly believe Cytokinetics is more favorable than its rivals.
Institutional & Insider Ownership
73.6% of Cytokinetics shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.2% of Cytokinetics shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Cytokinetics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Cytokinetics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cytokinetics||$106.41 million||$16.45 million||-4.91|
|Cytokinetics Competitors||$284.49 million||$34.10 million||64.83|
Cytokinetics’ rivals have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Cytokinetics beats its rivals on 7 of the 13 factors compared.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.